We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19.
- Authors
Tran, Thi Nhu Mai; May, Bruce Pearson; Ung, Trong Thuan; Nguyen, Mai Khoi; Nguyen, Thi Thuy Trang; Dinh, Van Long; Doan, Chinh Chung; Tran, The Vinh; Khong, Hiep; Nguyen, Thi Thanh Truc; Hua, Hoang Quoc Huy; Nguyen, Viet Anh; Ha, Tan Phat; Phan, Dang Luu; Nguyen, Truong An; Bui, Thi Ngoc; Tu, Tieu My; Nguyen, Thi Theo; Le, Thi Thuy Hang; Dong, Thi Lan
- Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing further illness and fatalities. Here, we report the development of a SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the spike (S) protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG and neutralizing antibodies in three animal models: BALB/c mouse, Syrian hamster, and a non-human primate (Macaca leonina). In addition, a viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. Nanocovax did not induce any adverse effects in mice (Mus musculus var. albino) and rats (Rattus norvegicus). These preclinical results indicate that Nanocovax is safe and effective.
- Subjects
COVID-19; COVID-19 pandemic; COVID-19 vaccines; SARS-CoV-2; IMMUNE response
- Publication
Frontiers in Immunology, 2021, Vol 12, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2021.766112